SC
ITRM

Steven Cohen’s Iterum Therapeutics ITRM Stock Holding History

Steven Cohen’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-434,000
Closed -$668K – 2142
2024
Q1 		$668K Buy
+434,000
New +$705K ﹤0.01% 1566

Other funds holding ITRM

AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
KFS
Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BBPWM
Blue Bell Private Wealth Management Blue Bell, Pennsylvania $802M AUM 22.13% 1-Year Est. Return

Steven Cohen's ITRM Position: Q2 2024 in Review

Steven Cohen sold out of Iterum Therapeutics (ITRM) in Q2 2024, closing a stake of 434,000 shares — an estimated $668K sold.

Steven Cohen first reported a position in ITRM in Q1 2024 and held it in 1 quarter. The position peaked at $668K in Q1 2024. 15 funds tracked by Wall St. Rank hold ITRM as of Q2 2024.

  • Steven Cohen reported no remaining Iterum Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Steven Cohen sold 434,000 Iterum Therapeutics shares in Q2 2024, an estimated $668K.
  • Steven Cohen first reported a position in Iterum Therapeutics in Q1 2024 and held it in 1 quarter.
  • Steven Cohen's Iterum Therapeutics position peaked at $668K in Q1 2024.
  • 15 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2024.

Based on Point72 Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.